This is just the beginning! Our collection holds over 300 years of history, including rare newspapers, obituaries, marriage records, birth records, and so much more—most of which you won’t find anywhere else!
Drug Shrinks Colon Cancer in Terminal Patients
A targeted cancer drug IMC-C225 shows tumor reductions of at least 50 percent in about a quarter of end stage colon cancer patients. Researchers presented results from 120 participants at the ASCO meeting in San Francisco, signaling a potential new standard and prompting a forthcoming FDA filing by ImClone Systems.
MENTIONED IN THIS ARTICLE
San Francisco
Leonard Saltz
Memorial Sloan-Kettering Cancer Center
New York City
Saltz
ImClone Systems
Food and Drug Administration
Harlan Waksal
ImClone